⏱ News is delayed by 15 minutes. Sign in for real-time access.
Sign in
IDYA News
IDEAYA Biosciences, Inc. Common Stock
Quanterix Announces Board and Leadership Changes to Support Next Stage of Growth
businesswire.com
QTRX
TMO
ILMN
IDYA
MTD
IR
TROW
EXAS
SERA
IDEAYA Biosciences Reports Third Quarter 2025 Financial Results and Provides Business Update
prnewswire.com
IDYA
IDEAYA Biosciences Announces Inducement Grants under Nasdaq Listing Rule 5635(c)(4)
prnewswire.com
IDYA
IDEAYA Biosciences to Participate in Upcoming November 2025 Investor Relations Events
prnewswire.com
IDYA
Next-Generation Targeted Therapies Reshape Precision Oncology Landscape
prnewswire.com
GTBP
IDYA
ZYME
NVS
REGN
GTBP
IDYA
ZYME
NVS
REGN
IDEAYA Biosciences Announces Inducement Grants under Nasdaq Listing Rule 5635(c)(4)
prnewswire.com
IDYA
Breakthrough Therapy Designations Surge as $50B Cancer Drug Partnerships Reshape Market
prnewswire.com
ONCY
HCM
CGON
CCCC
IDYA
ONCY
HCM
CGON
CCCC
IDYA
IDEAYA Biosciences Announces Positive Data From Phase 1/2 Combination Trial of IDE397, a potential first-in-class MAT2A inhibitor, and Trodelvy® in MTAP-Deletion Urothelial Cancer
prnewswire.com
IDYA
IDEAYA Biosciences Announces Positive Interim Phase 2 Data for Darovasertib in the Neoadjuvant Setting of Primary Uveal Melanoma
prnewswire.com
IDYA
IDEAYA Biosciences and Hengrui Pharma Present Positive Phase 1 Data for IDE849 (SHR-4849), a Potential First-in-Class DLL3 TOP1 ADC, in Small Cell Lung Cancer at the IASLC 2025 World Conference on Lung Cancer
prnewswire.com
IDYA